Clinical, serologic and instrumental data of ten patients affected by sclerodermatous chronic graft versus host disease: Similarities and differences in respect to systemic sclerosis

International Journal of Immunopathology and Pharmacology

Volumn 23, Issue 1, 2010, Pages 373-377

  Barausse, G ^a   Caramaschi, Paola ^a   Scambi, C ^a   Benedetti, F ^a   Sorio, M ^a   Tinelli, M ^a   Tinazzi, I ^a   Benini, L ^a   Bambara, L M ^a   Biasi, D ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Sclerodermatous chronic graft versus host disease; Systemic sclerosis

Indexed keywords

ADULT; ARTICLE; BODY REGIONS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; LABORATORY TEST; MALE; MEDICAL RECORD; PRIORITY JOURNAL; SCLERODERMA; SEROLOGY; SYSTEMIC SCLEROSIS;

EID: 77951744149     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201002300139     Document Type: Article

References (10)

1. Schafer JV, Mc Niff JM, Seropian S, Cooper DL, Bologna JL. Lichen sclerosus and eosinophilic fasciitis as manifestation of chronic graft-versus-host disease: Expanding the sclerodermoid spectrum. J Am Acad Dermatol 2005; 53:591-601. (Pubitemid 41399925)
2. Penas PF, Jones-Caballero M, Aragues M, Fernández-Herrera J, Fraga J, García-Díez A. Sclerodermatous graft-versus host disease. Clinical and pathological study of 17 patients. Arch Dermatol 2002; 138:924-934
3. Nelson JL, Furst DE, Maloney S, Gooley T, Evans PC, Smith A, Bean MA, Ober C, Bianchi DW. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 1998; 351:559-62. (Pubitemid 28077562)
4. Zhang C, Todorov I, Zhang Z, Liu Y, Kandeel F, Forman S, Strober S, Zeng D. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Transplantation 2006; 107:2993-3001.
5. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 2002; 168:3088-3098 (Pubitemid 34211692)
6. Bell SA, Faust H, Mittermuller J, Kolb HJ, Meurer M. Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association. Br J Dermatol 1996; 134:848-54. (Pubitemid 26151399)
7. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED. Clinical manifestation of graft-versus host disease in human recipients of marrow from HLA-matched sibling donors. Transplantion 1974; 18:295-304.
8. Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-590
9. Svegliati S, Olivieri A, Campelli N, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007; 110:237-241 (Pubitemid 47026840)
10. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006; 354:2667-76. (Pubitemid 43920840)